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OBJECTIVES This study was conducted to evaluate follow-up results in patients with hypertrophic
obstructive cardiomyopathy (HOCM) who underwent either percutaneous transluminal
septal myocardial ablation (PTSMA) or septal myectomy.
BACKGROUND Controversy exists with regard to these two forms of treatment for patients with HOCM.
METHODS Of 51 patients with HOCM treated, 25 were treated by PTSMA and 26 patients via
myectomy. Two-dimensional echocardiograms were performed before both procedures,
immediately afterwards and at a three-month follow-up. The New York Heart Association
(NYHA) functional class was obtained before the procedures and at follow-up.
RESULTS Interventricular septal thickness was significantly reduced at follow-up in both groups (2.3 
0.4 cm vs. 1.9 0.4 cm for septal ablation and 2.4 0.6 cm vs. 1.7 0.2 cm for myectomy, both
p 0.001). Estimated by continuous-wave Doppler, the resting pressure gradient (PG) across the
left ventricular outflow tract (LVOT) significantly decreased immediately after the procedures in
both groups (64 39 mm Hg vs. 28 29 mm Hg for PTSMA, 62 43 mm Hg vs. 7 7 mm
Hg for myectomy, both p  0.0001). At three-month follow-up, the resting PG remained lower
in the PTSMA and myectomy groups (24  19 mm Hg and 11  6 mm Hg, respectively, vs.
those before procedures, both p  0.0001). The NYHA functional class was also significantly
improved in both groups (3.5  0.5 vs. 1.9  0.7 for PTSMA, 3.3  0.5 vs. 1.5  0.7 for
myectomy, both p  0.0001).
CONCLUSIONS Both myectomy and PTSMA reduce LVOT obstruction and significantly improve NYHA
functional class in patients with HOCM. However, there are benefits and drawbacks for each
therapeutic method that must be counterbalanced when deciding on treatment for LVOT
obstruction. (J Am Coll Cardiol 2001;38:1994–2000) © 2001 by the American College of
Cardiology
Hypertrophic obstructive cardiomyopathy (HOCM) is a
disease characterized by: hypertrophy of the interventricular
septum (IVS), a narrowed left ventricular (LV) outflow tract
(LVOT) and, frequently, systolic anterior motion (SAM) of
the mitral valve resulting in LVOT obstruction (1–3). The
aim of treatment is to reduce SAM to eliminate the pressure
gradient (PG) and the mitral insufficiency in order to
improve myocardial performance and symptoms. Several
therapeutic options have been suggested for treating pa-
tients with HOCM. Medications, including beta-
adrenergic blocking agents, verapamil and disopyramide, are
used for initial treatment. However, high doses of medica-
tion frequently required to treat the symptoms of HOCM
may produce side effects (4). Surgical septal myectomy has
been shown to be safe and effective for eliminating the
LVOT obstruction and improving symptoms (5–9). How-
ever, experience with myectomy is limited at many centers.
Several reports show that the role of dual pacemakers as an
option in the treatment of LVOT obstruction is still
controversial (10,11). Recently, a nonsurgical procedure,
percutaneous transluminal septal myocardial ablation
(PTSMA), has been introduced and might replace surgical
myectomy in some patients (12–18). Ethanol is infused into
one or more septal perforator branches of the left anterior
descending coronary artery to cause necrosis and then
shrinkage of the proximal hypertrophied septum, which
results in an enlargement of the narrowed LVOT. This
novel therapeutic modality might become standard treat-
ment for HOCM, but its results in comparison with
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myectomy are not clear. While we feel PTMSA is a viable
alternative to surgery, we have taken a cautious approach
with it. We have done it, for the most part, in elderly
patients or patients with other comorbid conditions because
we feel that this is an investigational procedure that has not
been definitively proven. Thus, the optimal treatment for
patients with HOCM refractory to medical therapy is still
unknown (19,20).
Several factors including age and risk of treatment mo-
dality might influence the clinical decision making when
choosing the optimal treatment to relieve LVOT obstruc-
tion in patients with HOCM who have failed to respond to
medical therapy. It is essential to understand the outcome of
these treatments and which candidates are best suited for
these two therapeutic modalities. We did not feel that
alcohol ablation was ready for randomization at the time of
this study or in its developmental stage. Therefore, the
purpose of this nonrandomized cohort study is to assess the
subjective and objective outcomes after PTSMA and surgi-
cal septal myectomy for the treatment of LVOT obstruction
in a single center’s population with HOCM.
METHODS
Patients. The study group consisted of 51 symptomatic
patients with HOCM who underwent septal myectomy
(n  26, mean age 48  13 years, men  16) or PTSMA
(n  25, mean age 63  14 years, men  7) and had three
months follow-up at the Cleveland Clinic Foundation from
March 1997 to November 1999. During the same time, a
total of 294 patients with hypertrophic cardiomyopathy
were seen, and approximately half of the patients required
an invasive therapeutic procedure (121 patients for myec-
tomy and 37 patients for PTSMA). All patients had
baseline echocardiography, immediately after the proce-
dures and at three months. Most of our patients who
underwent PTMSA did not require transesophageal echo-
cardiography (TEE) to evaluate the mitral valve. Only if
suitable images could not be obtained was TEE performed.
One patient required a TEE before deciding about the
suitability of PTMSA because of poor image quality, and
this patient had a TEE during the PTMSA so that the
septum could be properly imaged. The diagnosis of HOCM
was based on the presence of a hypertrophied, nondilated
LV. Other diseases capable of producing significant hyper-
trophy and systolic anterior motion of the mitral valve were
absent in these patients. In addition, each patient had
clinical symptoms characteristic of severe HOCM, such as
syncope in 12 patients (24%), angina in 22 patients (42%) or
dyspnea in 40 patients (78%) of at least New York Heart
Association (NYHA) functional class III. Patients with
resting or provokable LVOT gradient 50 mm Hg and
refractory to medical treatment were considered candidates
for these therapies (18,21). Percutaneous transluminal septal
myocardial ablation was usually recommended in patients
who were elderly and had other comorbid conditions that
could increase the risk of surgical therapy. When there was
felt to be a need for concomitant valvular surgery or if a
patient had a severe coronary artery disease, they were
excluded for the PTSMA. All patients gave informed
consent before these respective procedures.
Septal myectomy surgery. Standard cardiopulmonary by-
pass and myocardial preservation techniques were used
(7–9). After aortic cross clamping and aortotomy, a portion
of the septal muscle was excised. Then, another TEE was
performed. If there was no LVOT PG, isoproterenol was
infused, and the TEE was repeated to check for the
elimination of LVOT PG and for the reduction or elimi-
nation of mitral regurgitation before closure of the chest.
PTSMA. In brief, two catheters were placed in the LV and
ascending aorta to record simultaneous pressures and mea-
sure the PG across LVOT. Next, a balloon catheter was
introduced into the first septal branch of the left anterior
descending coronary artery. After the balloon was inflated,
the distribution of the first septal branch was verified by
contrast two-dimensional echocardiography after the injec-
tion of an echo contrast agent (18), Optison (Mallinckrodt
Inc., San Diego, California) 0.5 to 1 ml diluted 1 to 20,
through the catheter. If the first septal branch did not supply
the area of SAM septal contact, the second branch was
selected and retested. After confirming which territory of
the basal septum contributed to the LVOT obstruction and
no the other myocardial territory was involved, 1 to 3 ml
(average 2.7  1.0 ml) of alcohol was infused through the
catheter with the balloon inflated and maintained for
10 min. The LVOT PGs were measured before and
immediately after the procedures by catheter and by two-
dimensional echocardiography.
Echocardiography. For both myectomy and PTSMA pa-
tient groups, conventional two-dimensional echocardiogra-
phy and Doppler echocardiography was performed using a
Vingmed System Five (GE/Vingmed, Milwaukee, Wiscon-
sin) or a Sequoia 512 (Acuson, Mountain View, California)
before, immediately after the procedures and at follow-up.
All images were recorded on one-half inch VHS videotapes
with selected images and loops also stored on magneto-
optical disks in the DICOM format. Thickness of basal IVS
and posterior wall (PW) and diameters of the LV and left
atrium were measured using a standard M-mode echocar-
Abbreviations and Acronyms
HOCM  hypertrophic obstructive cardiomyopathy
IVS  interventricular septum
LV  left ventricle or left ventricular
LVOT  left ventricular outflow tract
NYHA  New York Heart Association
PG  pressure gradient
PTSMA  percutaneous transluminal septal myocardial
ablation
PW  posterior wall
SAM  systolic anterior motion of mitral leaflet
TEE  transesophageal echocardiography
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diogram, according to the recommendations of the Amer-
ican Society of Echocardiography. The ratio of IVS/PW
was calculated, and LV ejection fraction was assessed (22).
The degree of SAM of the mitral valve was divided into
three grades as follows: 1) mild SAM was defined as the
minimal mitral-septal distance 10 mm, 2) moderate
SAM, when the distance was 10 mm with only brief
mitral-septal contact (30% of systole), and 3) severe SAM,
when there was prolonged mitral-septal contact (30% of
systole) (23). Mitral regurgitation was assessed by color
Doppler and quantified by the flow convergence method
(24). Continuous-wave Doppler technique was used to
measure maximum velocity across LVOT with apical five-
or three-chamber view. Then, peak PG through LVOT was
estimated using the simplified Bernoulli equation (25). In
patients with resting PG 50 mm Hg, amyl nitrite inha-
lation was performed to check the presence of a provokable
gradient.
Criteria for evaluation of success. For both myectomy
and PTSMA patients, the procedures were considered
successful when resting PG was less than 16 mm Hg or
when the percentage of PG reduction was more than 50%
immediately after procedures and during follow-up
(13,16,26–28). The percentage (%) of PG reduction was
calculated as:
PG before procedure PG after procedure
PG before procedure
 100%
Follow-up study. After discharge, patients underwent a
comprehensive clinical evaluation, including assessment of
NYHA functional class, by a cardiologist at a mean
follow-up of 128  84 days for myectomy and 117  36
days for PTSMA (p  NS).
Statistical analysis. Data are presented as mean  SD.
Analysis of variance with repeated measures was used to
compare the values before and after the procedures and
during follow-up. Due to the small sample size of the
groups compared, paired Student t test was used (pre vs.
post, pre vs. follow-up and post vs. follow-up). To adjust for
the multiple comparisons being made, a p value 0.01 was
considered statistically significant. Chi-square tests were
used to assess differences in success rates and complications
between the two groups.
RESULTS
Characteristics of patients before procedures. There were
25 patients in the PTSMA group and 26 patients in the
myectomy group. More women were included in the
PTSMA group (n  18) than in the myectomy group (n 
10) (p  0.02). The patients in the PTSMA group were
significantly older (63  14 years, range: 39 to 85 years)
than those in the myectomy group (48  13 years, range: 30
to 70 years; p  0.001). The patients receiving PTSMA
were older and tended to have more comorbid conditions
that might increase the risk for surgery than those found in
patients receiving myectomy (18 [72%] vs. 10 [38%], p 
0.02) (Table 1). At the time of the procedures, 58% of
patients took beta-blocking agents, 30% of patients took
calcium channel blockers and 12% of patients took both
medications.
Echocardiographic parameters. There was no significant
difference in IVS thickness between the patients receiving
PTSMA and the patients receiving myectomy before the
procedures (Table 2). The IVS thickness was significantly
decreased in both groups at follow-up (2.3  0.4 cm vs.
1.9  0.4 cm for PTSMA, 2.4  0.6 cm vs. 1.7  0.2 cm
for myectomy, both p  0.001). The end-diastolic diameter
of the LV in the myectomy group was larger than that in the
PTSMA group before procedure (p  0.03). The end-
diastolic diameter of the LV was significantly increased after
PTSMA at follow-up (p  0.01) and tended to increase
after myectomy (p  0.6) (Table 2). For mitral regurgitant
volume and the degree of SAM, no significant difference
was found between the two groups before procedures, and
there was no difference at follow-up (Table 2). Mitral
regurgitant volumes and the degree of SAM in both groups
were significantly decreased during follow-up, as compared
with those before procedures.
LVOT pressure gradients after procedures. PTSMA. The
average resting PG of 25 patients decreased from 64 
Table 1. The Comorbid Conditions in Two Groups
PTSMA
(n  25)
Myectomy
(n  26)
p
Value
Patients with comorbid conditions* 18 10 0.02
Congestive heart failure 8 3 NS
Coronary artery disease 3 5 NS
Peripheral vascular disease 2 0 NS
Azotemia 4 1 NS
Hypertension 10 3 0.02
Diabetes 5 2 NS
Chronic obstructive pulmonary disease 3 1 NS
History of stroke 1 0 NS
*Comorbid condition is defined as one or multiple conditions described below in the
list.
PTSMA  percutaneous transluminal septal myocardial ablation.
Table 2. Echocardiographic Parameters Before and
After Procedures
PTSMA Myectomy
Baseline Follow-Up Baseline Follow-Up
LA (cm) 4.7  0.8 4.6  0.8 5.0  0.7 4.7  0.7
LVID (cm) 4.0  0.8 4.4  0.8* 4.4  0.7‡ 4.5  0.6
IVS (cm) 2.3  0.4 1.9  0.4† 2.4  0.6 1.7  0.2†
PW (cm) 1.5  0.4 1.4  0.3 1.4  0.5 1.4  0.2
EF (%) 62  5 60  6 63  7 58  5*
MR (ml) 23  12 9  3† 28  12 8  5*
SAM 1.4  1.1 0.6  0.8† 1.1  0.6 0.6  0.5†
*p  0.01; †p  0.001, comparison with those before procedures; ‡comparison with
ablation, p  0.03.
EF  left ventricular ejection fraction; IVS  thickness of interventricular septum;
LA  diameter of left atrium; LVID  end-diastolic diameter of left ventricle;
MR  mitral regurgitant volume; PTSMA  percutaneous transluminal septal
myocardial ablation; PW  thickness of posterior wall of left ventricle; SAM 
degree of systolic anterior motion of mitral valve.
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39 mm Hg to 28  29 mm Hg (p  0.0001) after PTSMA
and to 24  19 mm Hg (p  0.0001) at follow-up. Of these
25 patients, 12 had a post-PTSMA PG 16 mm Hg, and
five had 16 mm Hg but 50% reduction in PG. At
follow-up, 13 patients had PG 16 mm Hg, and nine
patients had 16 mm Hg but 50% reduction in PG.
Thus, between the post-procedure period and follow-up, an
additional five patients had further reduction in their gra-
dients. At three-month follow-up, three patients were
considered a failure.
We also analyzed 14 patients with resting PG 50 mm
Hg and 11 patients with resting PG 50 mm Hg, sepa-
rately. Left ventricular outflow tract PG decreased from
91  30 mm Hg to 38  33 mm Hg after PTSMA and to
33  20 mm Hg at follow-up (vs. before PTSMA, both
p  0.0001) in the high PG group (Fig. 1A). In 11 patients
with lower PG, the amyl nitrite induced provokable gradi-
ent decreased from 92  30 mm Hg to 44  22 mm Hg
after PTSMA (p  0.001) and to 55  41 mm Hg at
follow-up (p  0.03) (Fig. 2A).
In the late follow-up, one patient had the PTSMA
redone 15 months after initial PTSMA, and five others
underwent myectomy for the elimination of the remaining
obstruction because of continued symptoms. A permanent
pacemaker was implanted in all five myectomy patients
because complete atrioventricular block developed.
MYECTOMY. The average resting PG of 26 patients de-
creased from 62  43 mm Hg to 7  7 mm Hg (p 
0.0001) after myectomy and to 11  6 mm Hg (p 
0.0001) at follow-up. Of these 26 patients, 25 had a
postmyectomy PG 16 mm Hg. One patient had a
postmyectomy PG 16 mm Hg and with 50% reduction
in PG. At follow-up, 21 patients had PG 16 mm Hg, and
five patients had resting PG between 16 and 50 mm Hg.
Thus, between the postprocedure period and follow-up,
four patients had resting PG increase slightly, but it still
remained significantly lower as compared with that before
the procedure.
We also analyzed the 15 patients with resting PG
50 mm Hg and 11 patients with resting PG 50 mm Hg.
Left ventricular outflow tract PG decreased from 91 
35 mm Hg to 8  8 mm Hg immediately after myectomy
and to 13  7 mm Hg at follow-up (both p  0.0001)
in the high PG group (Fig. 1B). In 11 patients with
lower resting PG, the provokable gradient decreased from
86  26 mm Hg (induced by amyl nitrite) to 16  13 mm
Hg (induced by infusion of isoproterenol) in the operating
room after myectomy (p  0.0001) and to 28  22 mm Hg
(induced by amyl nitrite) at follow-up (p  0.0001) (Fig.
2B).
Comparison of both therapies for reduction of PG. Be-
fore the procedure, there was no significant difference for
resting PG between the two groups (Fig. 3). However, the
resting PGs were significantly lower in the myectomy group
than they were in the PTSMA group immediately after the
procedure and during follow-up. In 21 (81%) patients
Figure 1. Resting pressure gradients (PG) before and immediately after
percutaneous transluminal septal myocardial ablation (A) or myectomy (B)
and at three-month follow-up in patients with resting PG 50 mm Hg.
*in comparison with PGs before procedure, p  0.0001.
Figure 2. Provokable pressure gradients (PG) before and immediately after
percutaneous transluminal septal myocardial ablation (A) or myectomy (B)
and at three-month follow-up in patients with resting PG 50 mm Hg. In
comparison with PGs before procedure, *p  0.0001; †p  0.001; ‡p 
0.03.
Figure 3. Comparison of average pressure gradients (PG) between percu-
taneous transluminal septal myocardial ablation (PTSMA) and myectomy
group.
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receiving myectomy, the PG was completely eliminated,
while only 13 (52%) PTSMA patients showed a resting PG
16 mm Hg at follow-up time (p  0.03). Twenty-six
(100%) patients in the myectomy group and 19 (76%)
patients in the PTSMA group also showed a reduction of
PG 50% (p  0.01) at that time.
NYHA functional class. Before the procedures, each pa-
tient’s NYHA functional class was III (Fig. 4). Average
NYHA functional class was 3.5  0.5 for ablation patients
and 3.3  0.5 for myectomy patients (p  NS). All patients
felt better after the procedure in both groups except one
PTSMA patient. Average NYHA functional class was
significantly improved in both PTSMA patients (1.9  0.7,
p  0.001) and myectomy patients (1.5  0.7, p  0.001)
after the procedure. There was no significant difference for
NYHA functional class between the two groups during
follow-up (p  NS).
Untoward effects of both procedures. There were no
deaths in either myectomy or PTSMA patients within three
months after the procedures. Eleven patients had conduc-
tion system block after PTSMA (complete right bundle
branch block in nine and complete left bundle branch block
in two), while 16 patients had complete left bundle branch
block after myectomy, p  0.05. Permanent pacemakers
were required in six patients (24%) in the PTSMA group
and in two patients (7.7%) in the myectomy group, respec-
tively (p  0.05).
Hospital stay. The recovery after the procedure was much
quicker in the PTSMA patients than it was in the myec-
tomy patients (mean hospital stay: 5.6  2.3 days vs. 8.1 
3.5 days, p  0.01).
DISCUSSION
In this study, we found that PTSMA and myectomy could
reduce the hypertrophied septum, decrease LVOT obstruc-
tion and improve the NYHA functional class and maintain
these effects for three months. The reduction of LVOT PG
was more complete in patients receiving myectomy, while
the hospital stay was shorter in patients receiving PTSMA.
In our opinion, PTSMA may be more desirable for older
patients with HOCM with comorbid conditions.
Advantages and disadvantages of myectomy surgery. The
results of myectomy for patients with HOCM have signif-
icantly improved in the recent four decades (5–9). About
70% of patients with HOCM have reported substantial and
persistent symptomatic improvement for five or more years
after myectomy surgery (8,9,21). In more than 90% of
patients with HOCM, resting LVOT gradients were com-
pletely eliminated or greatly reduced (8,9,21). However,
myectomies are currently performed with experienced hands
only at selected centers in the world (9,29). Previously, the
surgical mortality appeared to be higher (10% to 17%)
among elderly patients and those with concomitant diseases
(30,31). Review of our myectomy experience reveals the
hospital mortality is 1.0% (2 deaths of 194 patients) for all
HOCM surgeries between 1994 and 1999, and the mortal-
ity reduces to zero for pure myectomy between 1997 and
1999. A group in Germany reported their operated mortal-
ities were 2% (6).
Benefits and drawbacks of PTSMA. The short-term re-
sults of PTSMA are excellent for the reduction of LVOT
obstruction (13,17,32). Previous studies report that mean
resting PGs significantly reduced from 60 mm Hg to 14 mm
Hg after PTSMA (13,17,32), and other studies with longer
follow-up (16,18,33) do not show any recurrence of obstruc-
tion over time. One- to two-year follow-up shows contin-
ued improvement in symptoms with a mean increase of over
one NYHA functional class (16,18,33). More importantly,
objective tests show increases of exercise time around 40%
over follow-up (18). Recently, Lakkis et al. (18) reported
results of a one-year follow-up study in 50 patients. In his
study, resting PGs dropped significantly from average 74 
23 mm Hg to 6  18 mm Hg, and dobutamine-induced
gradient decreased from 84  28 mm Hg to 30  33 mm
Hg. The exercise duration increased by 2 min at one year.
Similar results were also found in our study, with both
resting and provokable PGs significantly reduced immedi-
ately after the PTSMA and remaining lower after three
months.
Although PTSMA completely eliminated LVOT PGs in
most patients with HOCM, significant resting or provok-
able obstruction may remain in some others. There were
seven patients (7/50, 14%) in Lakkis’ et al. (18) study who
needed to have the procedure redone within one year after
the initial ablation. There was also some significant scatter
from the mean, as shown in our figures. This scatter was
wider for the PTSMA group at follow-up. Left ventricular
outflow tract obstruction is not only caused by hypertrophy
of IVS but also by anterior movement of mitral valve
leaflets. Percutaneous transluminal septal myocardial abla-
tion will only cause reduction of the septum. If there is
elongation of the anterior or posterior leaflet of the mitral
valve, PTSMA will not be sufficient to relieve the outflow
tract obstruction. In addition, recent data in abstract form
from Faber et al. (34) suggests that patients with “thicker
septums” obtain less success in reducing the gradient. One
patient in our study who underwent PTSMA initially had
Figure 4. Improvements in New York Heart Association (NYHA) func-
tional class after percutaneous transluminal septal myocardial ablation and
myectomy in patients with hypertrophic obstructive cardiomyopathy.
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no gradient reduction because of an elongated anterior
leaflet. When she underwent surgery, mitral valve repair was
needed in addition to myectomy to completely abolish her
gradient. Five PTSMA patients in our study subsequently
underwent myectomy to eliminate the obstruction (one due
to dissection of ascending aorta late after PTSMA, one due
to elongation of mitral valve leaflets and cause for remaining
three patients is unclear).
The overall requirement for pacing is 21%, varying from
0% to 40% among different reports, and the mortality is 2%
for PTSMA (13,15,17,26,33). A total of 24% of PTSMA
patients in our study needed permanent pacemakers after
the procedure, while 7.7% patients needed them after
myectomy. However, if myectomy is required after a failed
PTMSA, there is a high likelihood that the patient will
require a permanent pacemaker. The right bundle is usually
supplied by the proximal septal perforators, and, thus,
PTMSA frequently leads to complete right bundle branch
block, and septal myectomy causes complete left bundle
branch block in a majority of patients. So if a patient has
both procedures, it is quite likely that complete heart block
will develop. Despite the high incidence of permanent
pacemaker insertion when both procedures are required,
subsequent myectomy is not difficult.
In comparison with myectomy, however, PTSMA obvi-
ously has distinct advantages. Percutaneous transluminal
septal myocardial ablation is a less invasive technique and
has shorter hospital stay. Therefore, both physicians and
patients may prefer PTSMA rather than myectomy in the
treatment of HOCM as an initial nonpharmacologic inter-
vention. Percutaneous transluminal septal myocardial abla-
tion is an exciting alternative therapeutic strategy for older
patients with HOCM with concomitant disease or higher-
risk surgery. However, some patients do not derive enough
relief immediately from the PTMSA, and months are
required for reduction in the gradient, a potential disadvan-
tage of the procedure for some patients. In the last five years,
more than 1,000 patients with HOCM have undergone
PTSMA worldwide (35). In addition, if the PTSMA fails,
myectomy can still be performed, but a permanent pace-
maker is almost always needed. In our experience, all five
patients who underwent both procedures had permanent
pacemakers implanted when both procedures were required.
Study limitations. Our follow-up is relatively short in this
nonrandomized study, and the longer-term results are
unknown at this point. The groups are dissimilar in several
respects. There were no criteria for dividing patients into
PTSMA and myectomy groups. The general, accepted
patient selection criteria for PTSMA and myectomy is
based on marked LVOT PG under basal conditions
(LVOT PG  50 mm Hg) or a provokable PG 50 mm
Hg and severe symptoms (NYHA functional class III or IV)
that fail to cease with medication (21). In this study, the
procedures were chosen based on patient and physician
preference. However, if the patient was elderly or had
significant comorbid conditions, PTSMA was strongly
suggested. Thus, in our study elderly patients more often
had PTSMA while younger patients had myectomy. Similar
reduction in LVOT obstruction by PTSMA occurred in
younger patients, as compared with myectomy, in the latest
study by Nagueh et al. (36) when patient’s age and LVOT
PG were matched. However, for elderly patients, especially
with concomitant disease, the less aggressive and less
invasive approach of PTSMA may be a better, or the only,
choice, even with incomplete elimination of the LVOT
obstruction.
CONCLUSIONS
Both myectomy and PTSMA reduce LVOT obstruction
and improve NYHA functional class significantly in pa-
tients with HOCM. However, there are benefits and
drawbacks for each therapeutic method that must be coun-
terbalanced when deciding on treatment for LVOT ob-
struction.
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